CA224, a non-planar analogue of fascaplysin, inhibits Cdk4 but not Cdk2 and arrests cells at G0/G1 inhibiting pRB phosphorylation

Bioorganic and Medicinal Chemistry Letters

Volumn 16, Issue 16, 2006, Pages 4272-4278

  Mahale, Sachin ^a   Aubry, Carine ^b   James Wilson, A ^b   Jenkins, Paul R ^b   Maréchal, Jean Didier ^b   Sutcliffe, Michael J ^b   Chaudhuri, Bhabatosh ^a  

^a DE MONTFORT UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Cell cycle; Cell growth inhibition; Cyclin dependent kinases; DNA intercalation; G0 G1 arrest; pRB

Indexed keywords

ANTINEOPLASTIC AGENT; CA 192; CA 218; CA 219; CA 220; CA 221; CA 222; CA 223; CA 224; CA 225; CA 226; CA 228; CA 229; CA 230; CA 233; CA 234; CA 237; CA 238; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR; DNA; FASCAPLYSIN; RETINOBLASTOMA PROTEIN; TRYPTAMINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CONTROLLED STUDY; DRUG DNA BINDING; DRUG IDENTIFICATION; DRUG POTENCY; DRUG SPECIFICITY; DRUG SYNTHESIS; ENZYME INHIBITION; ENZYME SPECIFICITY; EXPECTATION; HUMAN; HUMAN CELL; IC 50; INTERCALATION COMPLEX; PROTEIN PHOSPHORYLATION;

ANTINEOPLASTIC AGENTS; BIPHENYL COMPOUNDS; CHEMISTRY, PHARMACEUTICAL; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE 4; DNA; DRUG DESIGN; G0 PHASE; G1 PHASE; INDOLES; INHIBITORY CONCENTRATION 50; MODELS, CHEMICAL; PHOSPHORYLATION; RETINOBLASTOMA PROTEIN;

EID: 33745727153     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2006.05.065     Document Type: Article

References (17)

1. Roll D.M., Ireland C.M., Lu H.S.M., and Clardy J. J. Org. Chem. 53 (1988) 3276
2. Soni R., Muller L., Furet P., Schoepfer J., Stephan C., Zumstein-Mecker S., Fretz H., and Chaudhuri B. Biochem. Biophys. Res. Commun. 275 (2000) 877
3. Sherr C.J. Science 274 (1996) 1672
4. Malumbres M., and Barbacid M. Cancer Cell 9 (2006) 2
5. Yu Q., Sicinska E., Geng Y., Ahnstrom M., Zagozdzon A., Kong Y., Gardner H., Kiyokawa H., Harris L.N., Stal O., and Sicinski P. Cancer Cell 9 (2006) 23
6. Landis M.W., Pawlyk B.S., Li T., Sicinski P., and Hinds P.W. Cancer Cell 9 (2006) 13
7. Tetsu O., and McCormick F. Cancer Cell 3 (2003) 233
8. Fischer P.M., Endicott J., and Meijer L. Prog. Cell Cycle Res. 5 (2003) 235
9. Segraves N.L., Robinson S.J., Garcia D., Said S.A., Fu X., Schmitz F.J., Pietraszkiewicz H., Valeriote F.A., and Crews P. J. Nat. Prod. 67 (2004) 783
10. Subramanian B., Nakeff A., Tenney K., Crews P., Gunatilaka L., and Valeriote F. J. Exp. Ther. Oncol. 5 (2006) 195
11. Hormann A., Chaudhuri B., and Fretz H. Bioorg. Med. Chem. 9 (2001) 917
12. Aubry C., Jenkins P.R., Mahale S., Chaudhuri B., Marechal J.D., and Sutcliffe M.J. Chem. Commun. (Camb.) 7 (2004) 1696
13. Aubry C., Patel A., Mahale S., Chaudhuri B., Marechal J.D., Sutcliffe M.J., and Jenkins P.R. Tetrahedron Lett. 46 (2005) 1423
14. Aubry C., Wilson A.J., Jenkins P.R., Mahale S., Chaudhuri B., Marechal J.D., and Sutcliffe M.J. Org. Biomol. Chem. 4 (2006) 787
15. Geall A.J., Eaton M.A., Baker T., Catterall C., and Blagbrough I.S. FEBS Lett. 45 (1999) 337
16. Brotz-Oesterhelt H., Knezevic I., Bartel S., Lampe T., Warnecke-Eberz U., Ziegelbauer K., Habich D., and Labischinski H. J. Biol. Chem. 278 (2003) 39435
17. Fortune J.M., and Osheroff N. J. Biol. Chem. 273 (1998) 17643